119285-07-3

Basic information

• Product Name: 4-(5-AMINOPYRIDIN-2-YL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 1-BOC-4-(5-AMINO-PYRIDIN-2-YL)-PIPERAZINE;4-(5-AMINOPYRIDIN-2-YL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;TERT-BUTYL 4-(5-AMINO-2-PYRIDINYL)TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE;4-(5-Aminopyridin-2-yl)piperazine-1-carboxylicacidtert-butylester95%;4-(5-Aminopyridin-2-yl)qiperazine-1-carboxylic acid tert-butyl ester;4-(5-AMINOPYRIDIN-2-YL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER 95%;4-(5-Aminopyridin-2-yl)piperazine, N1-BOC protected;1-Boc-4-(5-amino-2-pyridinyl)-piperazine
• CAS NO: 119285-07-3
• Molecular Formula: C₁₄H₂₂N₄O₂
• Molecular Weight: 278.35
• Product Categories: pharmacetical
• Mol File: 119285-07-3.mol
• Article Data: 28

Chemical Properties

• Melting Point: 98-101°C
• Boiling Point: 470.4°Cat760mmHg
• Flash Point: 238.3°C
• Appearance: /
• Density: 1.182g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.569
• Storage Temp.: 2-8°C(protect from light)
• PKA: 9.35±0.29(Predicted)
• CAS DataBase Reference: 4-(5-AMINOPYRIDIN-2-YL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(5-AMINOPYRIDIN-2-YL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(119285-07-3)
• EPA Substance Registry System: 4-(5-AMINOPYRIDIN-2-YL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(119285-07-3)

Safety Data

• Hazard Codes: Xi,T
• Statements: 25
• Safety Statements: 45
• HazardClass: IRRITANT
• Hazardous Substances Data: 119285-07-3(Hazardous Substances Data)

Usage

General Description

4-(5-Aminopyridin-2-yl)piperazine-1-carboxylic Acid Tert-butyl Ester is a chemical compound that is typically utilized in the field of medicinal chemistry and pharmaceuticals. It belongs to a larger group of complex substances often employed in drug discovery and development processes due to their bioactive properties. This specific compound is characterized by its molecular inclusion of a pyridinyl group, an aminopyridine moiety, a piperazine ring, and a carboxylic acid ester structure. Its participation in various interactions within biological processes provides a foundation for potential therapeutic applications. The precise biochemical effects, toxicology information, and other specifics regarding this compound are subject to scientific research and may vary depending on the context of use.

InChI:InChI=1/C14H22N4O2/c1-14(2,3)20-13(19)18-8-6-17(7-9-18)12-5-4-11(15)10-16-12/h4-5,10H,6-9,15H2,1-3H3

Upstream product

• 4487-59-6 2-bromo-5-nitropyridine 
• 4548-45-2 2-chloro-5-nitropyridine 
• 1227862-58-9 5'-amino-4-phenyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-ol 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 82205-58-1 1-(5-nitro-2-pyridinyl)piperazine 
• 193902-78-2 tert-butyl 4-(5-nitropyridin-2-yl)piperazine-1-carboxylate 

Downstream Products

• 1085841-68-4 2-phenyl-N-[6-piperazin-1-ylpyridin-3-yl]-5-trifluoromethyl-1,3-oxazole-4-carboxamide hydrochloride 
• 1331778-53-0 C₂₁H₂₆N₄O₄ 

Relevant articles and documents

Identification of 2-aminooxazole amides as acyl-CoA: Diacylglycerol acyltransferase 1 (DGAT1) inhibitors through scaffold hopping strategy

A scaffold hopping strategy was successfully applied in discovering 2-aminooxazole amides as potent DGAT1 inhibitors for the treatment of dyslipidemia. Further optimization in potency and PK properties resulted in a lead series with oral in vivo efficacy in a mouse postprandial triglyceridemia (PPTG) assay.

SMALL MOLECULE INHIBITORS OF GALECTIN-3

The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions. (Formula (I))

5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, Darier's disease, scleroderma, cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.